From Policy to Practice: Europe's Integrated Approach to Medicine Security
Day 1 Global Pharma Outlook Stage
06/10/2026 11:05 - 11:50am
Contributors
Monika Derecque-Pois : Founder - HCI- the Healthcare Chain Institute
Mariagrazia Sturniolo : Sr Dir. EU Supply Chain Teva Pharmaceuticals - Teva Pharmaceuticals
Roberta Pizzocaro : President - Olon Group
Marco Farinelli : Chair of the Supply Chain WG - Efpia | Global Supply Chain Director - AstraZeneca
Kelsey Achenbach : Vice President, Pharmaceutical Business - dsm-firmenich
The European Union's simultaneous deployment of the Critical Medicines Act, EU Pharma Package, and EU Biotech Act marks an unprecedented attempt to restructure pharmaceutical governance around strategic autonomy rather than market efficiency. This panel addresses the complex reality of translating coordinated policy intent into operational outcomes across fragmented regulatory environments.
While policy frameworks emphasize medicines as strategic assets requiring supply chain diversification, existing economic mechanisms continue to prioritize cost optimization over security considerations. This creates what industry stakeholders describe as "responsibility without authority," where manufacturers bear accountability for achieving strategic objectives without corresponding economic incentives.The panel will explore how industry leaders are navigating these structural tensions and adapting to Europe's transformed regulatory landscape.